Daniel O’Day, Chairman and Chief Executive Officer at Gilead Sciences, shared a post on LinkedIn:
“This week, Gilead announced a very strong Q2 performance driven by growing uptake of our therapies for HIV, cancer, and liver disease. The double-digit growth in the base business, the recent approvals for new medicines, and several positive clinical trial updates all speak to the quality of our innovation and the excellent performance of our teams.
With another two potential launches ahead this year, and a growing pipeline, we look forward to further increasing our impact for patients and communities worldwide. Many thanks to the colleagues and partners around the world who make our progress possible.”